Short answer: most likely, yes. Clearly, navigating emerging markets will require a great deal of time and effort by pharma. These markets are highly dynamic, and the regional variations in ...

John Arena is interim president of global pharma services at Cencora, managing a team that offers a broad range of solutions ...

What should pharma do in Emerging Markets? The initial enthusiasm that erupted when emerging markets first demonstrated their potential has often given way to disappointment, as early—and ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...

Indian drugmakers earn a significant share of revenue from the U.S., the largest importer of Indian pharma products. India's pharma exports to the country stood at $8.73 billion in fiscal 2024 - a ...

Role of emerging technologies in the success of consumer-tech companies - Akhil Gupta, Co-Founder & CTO, NoBroker Jobs of the next decade: Impact of COVID19 on job creation in consumer-tech space ...

with Aurobindo Pharma and Lupin emerging as the top losers, plunging 6.2% and 4.5%, respectively. The index dropped 3.2% in early trade, hitting the day's low of 20,299. Trump, on Tuesday ...

“While buying stocks during a market correction may seem appealing, it is prudent to wait for market conditions to stabilize before making investment decisions,” says Mayuresh Joshi, Head of ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...